Moderna has signed an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) for delivering an additional 70 million doses of its Covid-19 booster vaccine or an updated booster vaccine candidate.
The modified booster vaccine candidate will be supplied on obtaining authorisation in the region.
The company intends to supply the vaccine doses to Japan in the second half of this year.
Moderna noted that the deal is subject to the MHLW obtaining funds to secure the additional vaccine doses.
A total of 93 million Covid-19 vaccine doses are presently committed to be delivered to Japan this year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Furthermore, under the latest deal, the doses could potentially be raised to 163 million.
In May last year, the Japanese ministry granted special approval for the emergency use of Moderna’s Covid-19 vaccine.
The vaccine is intended for active immunisation for the prevention of Covid-19.
A booster dose of the vaccine is intended to be administered a minimum of six months following the second dose in individuals aged 18 years and above.
Moderna announced in October 2020 that the MHLW and Takeda Pharmaceutical agreed to procure and supply 50 million doses of its Covid-19 vaccine.
The vaccine will be manufactured and delivered by Moderna under the agreement while Takeda will handle the regulatory approvals for vaccine supply in the country.
In February, Moderna entered a new supply agreement to deliver an additional 10.8 million doses of its Covid-19 vaccine, Spikevax, to the Government of Colombia.
The Colombian National Institute for Food and Drug Surveillance (INVIMA) had granted emergency use authorization (EUA) for the vaccine for active immunisation regarding the prevention of Covid-19 in individuals aged 12 years and older.
